TO UNDERSTAND THE SCALE WE MUST SURVEIL

Effective surveillance is a critical part of antimicrobial stewardship. Collective efforts to monitor changes in pathogen resistance patterns and susceptibility can strengthen our understanding of how antimicrobial resistance is evolving, helping to prevent, control, and treat infections.¹

Bodies around the world are seeking to establish a complete picture of emerging resistance through surveillance programs. The World Health Organization’s (WHO) GLASS (the Global Antimicrobial Resistance and Use Surveillance System) is one example.^2,3 Since 2015 it has offered a standardized approach to the collection and interpretation of data, while monitoring antimicrobial use and resistance in humans, the food chain, and the environment.^2,3


SURVEILLING THE WORLD WITH ATLAS

At Pfizer, we have one of the world’s largest AMR surveillance website platforms: ATLAS (Antimicrobial Testing Leadership and Surveillance).^1,4

The ATLAS program was initiated in 2004. Our searchable, interactive mobile app and website launched in 2017 with almost 20 years of cumulative data on emerging pathogen resistance and sensitivity patterns from over 80 countries.^1,4

ATLAS was highlighted by the 2020 and 2021 Access to Medicines Benchmark Reports on AMR, as Pfizer remains the only company to publicly share results and raw data on resistance patterns.^1,5–6

In 2020, ATLAS further expanded with the integration of data from SENTRY, one of the longestrunning antimicrobial surveillance programs in the world – adding much-needed antifungal information.^1,4